We studied inter-laboratory variation in ER, PR, and HER2 positivity rates in a nationwide cohort of 33,046 invasive breast cancer patients, using real-life data from synoptic pathology reports of the Dutch nationwide pathology registry (PALGA). Here, ERBB2 is linked to invasive breast carcinoma.